EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2025

EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2025

  • November 2017 •
  • 47 pages •
  • Report ID: 5238260 •
  • Format: PDF
EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2025

Summary
Chronic lymphocytic leukemia (CLL), also known as chronic lymphoid leukemia, is a type of cancer of the white blood cells (lymphocytes). CLL affects a particular lymphocyte, the B cell, which accumulates mainly in the bone marrow and blood, and normally fights infection. In CLL, the DNA of a B cell is damaged so that it cannot fight infection, but instead, it grows out of control and affects the healthy blood cells that can fight infection (NCI, 2016). CLL is closely related to small lymphocytic lymphoma (SLL), a type of non-Hodgkin’s lymphoma that presents primarily in the lymph nodes.

In the 7MM, epidemiologists forecast an increase in the diagnosed incident cases of CLL from 40,631 diagnosed incident cases in 2015 to 49,643 diagnosed incident cases in 2025, with an annual growth rate (AGR) of 2.22% during the forecast period. The US will have the highest number of diagnosed incident cases of CLL among the 7MM throughout the forecast period, while Spain will have the lowest.

The report "EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2025" provides an overview of the risk factors, comorbidities, and the global and historical trends for CLL in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Canada). The report includes a 10-year epidemiological forecast for the diagnosed incident cases of CLL segmented by age (for ages 18 years and older) and sex. Additionally, the CLL diagnosed incident cases are segmented by Rai and Binet stage at diagnosis, symptom status (symptomatic vs. asymptomatic), and immunoglobulin heavy chain variable (IGHV) region gene mutation status (mutated vs. unmutated) for the 7MM.

Scope
- The Chronic lymphocytic leukemia (CLL) EpiCast Report provides an overview of the risk factors and global trends of CLLin the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report includes a 10-year epidemiological forecast for the diagnosed incident cases of CLL and five-year diagnosed prevalent cases of CLL. Incident cases are segmented by age, sex, Rai and Binet stage at diagnosis, symptom status (symptomatic vs. asymptomatic), and immunoglobulin heavy chain variable (IGHV) region gene mutation status (mutated vs. unmutated) for the 7MM. The diagnosed incident cases of CLL with the mutations 17p deletion, 11q deletion, and TP53 are also provided in the report.
- The CLL epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy
The CLL EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global CLL market.
- Quantify patient populations in the global CLL market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CLL therapeutics in each of the markets covered.
- Understand magnitude of CLL population by two staging systems.
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.